Hepatotoxicity is the risk factor with gemtuzumab ozogamicin treatment in acute myelogenous leukaemia patients

Affiliations

• ¹ Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacology, Jamia Hamdard (Hamdard University), New Delhi, India; Department of Pharmacy, Al Baha University, Kingdom of Saudi Arabia. Electronic address: sayedaliulhasan@gmail.com.
• ² Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, Government of India, Sector-23, Raj Nagar, 201002 Ghaziabad, UP, India.
• ³ Department of Medical Elementology & Toxicology, Jamia Hamdard (Hamdard University), New Delhi, India.
• ⁴ Department of Pharmacy, Al Baha University, Kingdom of Saudi Arabia.